Skip to main content
Top
Published in: Journal of Nephrology 6/2014

01-12-2014 | Original Article

Adherence to phosphate binders in hemodialysis patients: prevalence and determinants

Authors: Yoleen P. M. Van Camp, Bernard Vrijens, Ivo Abraham, Bart Van Rompaey, Monique M. Elseviers

Published in: Journal of Nephrology | Issue 6/2014

Login to get access

Abstract

Background

Phosphate control is a crucial treatment goal in end-stage renal disease, but poor patient adherence to phosphate binder therapy remains a challenge. This study aimed to estimate the extent of phosphate binder adherence in hemodialysis patients and to identify potential determinants.

Methods

Phosphate binder adherence was measured blindly in 135 hemodialysis patients for 2 months using the medication event monitoring system. Patient data, gathered at inclusion through medical records, ad hoc questionnaires and the short form (SF)-36 health survey, included: (1) demographics, (2) perceived side-effects, belief in benefit, self-reported adherence to the therapy, (3) knowledge about phosphate binder therapy, (4) social support, and (5) quality of life (SF-36). Phosphatemia data was collected from charts. ‘Being adherent’ was defined as missing <1 total daily dose/week and ‘being totally adherent’ as missing <1 total daily dose/week, every week.

Results

Mean age of patients was 67 years and 64 % of the sample was male. Over the 2 months, 78 % of the prescribed doses were taken. Every week, about half of patients were adherent. Over the entire 8-week period, 22 % of patients were totally adherent. Mean phosphatemia levels were 0.55 mg/dl lower in adherent than nonadherent patients (4.76 vs. 5.31 mg/dl). Determinants for being totally adherent were living with a partner, higher social support (both were interrelated) and higher physical quality of life. Experiencing intake-related inconvenience negatively affected adherence. The social support and quality of life physical score explained 26 % of the variance in adherence.

Conclusions

Phosphate binder nonadherence remains a major problem. Interventions should aim, at least, to improve social support. With few associated factors found and yet low adherence, an individualized approach seems indicated.
Appendix
Available only for authorised users
Literature
1.
go back to reference Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transpl 26(6):1948–1955CrossRef Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transpl 26(6):1948–1955CrossRef
2.
go back to reference Terai K, Nara H, Takakura K et al (2009) Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol 156(8):1267–1278PubMedCentralPubMedCrossRef Terai K, Nara H, Takakura K et al (2009) Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol 156(8):1267–1278PubMedCentralPubMedCrossRef
5.
6.
go back to reference Karamanidou C, Clatworthy J, Weinman J, Horne R (2008) A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9(2) Karamanidou C, Clatworthy J, Weinman J, Horne R (2008) A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 9(2)
7.
go back to reference Hung KY, Liao SC, Chen TH, Chao MC, Chen JB (2013) Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis. Ther Apher Dial 17(1):72–77PubMedCrossRef Hung KY, Liao SC, Chen TH, Chao MC, Chen JB (2013) Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis. Ther Apher Dial 17(1):72–77PubMedCrossRef
8.
go back to reference Schmid H, Hartmann B, Schiffl H (2009) Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res 14(5):185–190PubMedCentralPubMedCrossRef Schmid H, Hartmann B, Schiffl H (2009) Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res 14(5):185–190PubMedCentralPubMedCrossRef
9.
go back to reference Osterberg L, Blaschke T (2005) Drug therapy—adherence to medication. N Engl J Med 353(5):487–497PubMedCrossRef Osterberg L, Blaschke T (2005) Drug therapy—adherence to medication. N Engl J Med 353(5):487–497PubMedCrossRef
10.
go back to reference Aaronson NK, Muller M, Cohen PDA et al (1998) Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 51(11):1055–1068PubMedCrossRef Aaronson NK, Muller M, Cohen PDA et al (1998) Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 51(11):1055–1068PubMedCrossRef
11.
go back to reference Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A (2010) Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 23(5):525–534PubMed Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A (2010) Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 23(5):525–534PubMed
12.
go back to reference Pruijm M, Teta D, Halabi G, Wuerzner G, Santschi V, Burnier M (2009) Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients. Clin Nephrol 72(3):199–205PubMedCrossRef Pruijm M, Teta D, Halabi G, Wuerzner G, Santschi V, Burnier M (2009) Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients. Clin Nephrol 72(3):199–205PubMedCrossRef
13.
go back to reference Van Camp YP, Van Rompaey B, Elseviers MM (2013) Nurse-led interventions to enhance adherence to chronic medication: systematic review and meta-analysis of randomised controlled trials. Eur J Clin Pharmacol 69(4):761–770PubMedCrossRef Van Camp YP, Van Rompaey B, Elseviers MM (2013) Nurse-led interventions to enhance adherence to chronic medication: systematic review and meta-analysis of randomised controlled trials. Eur J Clin Pharmacol 69(4):761–770PubMedCrossRef
14.
go back to reference Hutchison AJ, Laville M, SPDLS Grp (2008) Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transpl 23(11):3677–3684CrossRef Hutchison AJ, Laville M, SPDLS Grp (2008) Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transpl 23(11):3677–3684CrossRef
15.
go back to reference Lindberg M, Lindberg P (2008) Overcoming obstacles for adherence to phosphate binding medication in dialysis patients: a qualitative study. Pharm World Sci 30(5):571–576PubMedCrossRef Lindberg M, Lindberg P (2008) Overcoming obstacles for adherence to phosphate binding medication in dialysis patients: a qualitative study. Pharm World Sci 30(5):571–576PubMedCrossRef
16.
go back to reference Wileman V, Chilcot J, Norton S, Hughes L, Wellsted D, Farrington K (2011) Choosing not to take phosphate binders: the role of dialysis patients’ medication beliefs. Nephron Clin Pract 119(3):C205–C213PubMedCrossRef Wileman V, Chilcot J, Norton S, Hughes L, Wellsted D, Farrington K (2011) Choosing not to take phosphate binders: the role of dialysis patients’ medication beliefs. Nephron Clin Pract 119(3):C205–C213PubMedCrossRef
17.
go back to reference Browne T, Merighi JR (2010) Barriers to adult hemodialysis patients’ self-management of oral medications. Am J Kidney Dis 56(3):547–557PubMedCrossRef Browne T, Merighi JR (2010) Barriers to adult hemodialysis patients’ self-management of oral medications. Am J Kidney Dis 56(3):547–557PubMedCrossRef
18.
go back to reference Garcia-Llana H, Remor E, Selgas R (2013) Adherence to treatment, emotional state and quality of life in patients with end-stage renal disease undergoing dialysis. Psicothema 25(1):79–86PubMed Garcia-Llana H, Remor E, Selgas R (2013) Adherence to treatment, emotional state and quality of life in patients with end-stage renal disease undergoing dialysis. Psicothema 25(1):79–86PubMed
Metadata
Title
Adherence to phosphate binders in hemodialysis patients: prevalence and determinants
Authors
Yoleen P. M. Van Camp
Bernard Vrijens
Ivo Abraham
Bart Van Rompaey
Monique M. Elseviers
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 6/2014
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-014-0062-3

Other articles of this Issue 6/2014

Journal of Nephrology 6/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.